BG106180A - Фармацевтичен състав, съдържащ сибутрамин и орлистат - Google Patents

Фармацевтичен състав, съдържащ сибутрамин и орлистат

Info

Publication number
BG106180A
BG106180A BG106180A BG10618001A BG106180A BG 106180 A BG106180 A BG 106180A BG 106180 A BG106180 A BG 106180A BG 10618001 A BG10618001 A BG 10618001A BG 106180 A BG106180 A BG 106180A
Authority
BG
Bulgaria
Prior art keywords
orlistat
pharmaceutical composition
composition containing
containing sibutramine
human
Prior art date
Application number
BG106180A
Other languages
English (en)
Inventor
David Heal
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of BG106180A publication Critical patent/BG106180A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Изобретението се отнася до метод за лечение на заболявания, съпътстващи затлъстяване при хора. Методът включва прилагане на терапевтично ефективно количество от съединение с формула@СН3@Н3ССНСН2СНNR1R2 включително негови енантиомери и фармацевтично приемливи соли, в която формула R1 и R2, независимо един от друг, са водород или метил, и на терапевтично ефективно количество от съединение с формула. Посочените съединения се прилагат заедно, разделно или последователно.
BG106180A 1999-06-24 2001-12-04 Фармацевтичен състав, съдържащ сибутрамин и орлистат BG106180A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9914744.9A GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents
PCT/EP2000/005542 WO2001000205A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat

Publications (1)

Publication Number Publication Date
BG106180A true BG106180A (bg) 2002-08-30

Family

ID=10855955

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106180A BG106180A (bg) 1999-06-24 2001-12-04 Фармацевтичен състав, съдържащ сибутрамин и орлистат

Country Status (21)

Country Link
EP (1) EP1187606A1 (bg)
JP (1) JP2003503349A (bg)
KR (1) KR20020015357A (bg)
CN (1) CN1358092A (bg)
AU (1) AU5533200A (bg)
BG (1) BG106180A (bg)
BR (1) BR0011880A (bg)
CA (1) CA2375972A1 (bg)
CZ (1) CZ20014613A3 (bg)
GB (1) GB9914744D0 (bg)
HK (1) HK1049278A1 (bg)
HU (1) HUP0201878A3 (bg)
IL (1) IL147079A0 (bg)
MX (1) MXPA01012936A (bg)
NO (1) NO20016224L (bg)
PL (1) PL352402A1 (bg)
RU (1) RU2229289C2 (bg)
SK (1) SK18242001A3 (bg)
TR (1) TR200103699T2 (bg)
WO (1) WO2001000205A1 (bg)
ZA (1) ZA200109989B (bg)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
RU2007119315A (ru) 2004-10-25 2008-11-27 Зольвай Фармасьютиклз Гмбх (De) Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
BRPI0716952A2 (pt) * 2006-09-15 2013-10-29 Reviva Pharmaceuticals Inc Composto, métodos para tratar e/ou prevenir obesidade ou indicação co-mórbida relacionada à obesidade, e para sintetizar derivado de cicloalquilmetilamina
JP2010510306A (ja) * 2006-11-22 2010-04-02 エスケー ケミカルズ カンパニー リミテッド シブトラミンとベータ−シクロデキストリンの包接複合体
CN101890017A (zh) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 含有西布曲明和他汀类降脂药物的药物组合物及其用途
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
MX336980B (es) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
RU2642074C2 (ru) 2011-12-30 2018-01-24 Ревива Фармасьютикалс, Инк. Композиции, синтез и способы применения производных фенилциклоалкилметиламина

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
KR20020015357A (ko) 2002-02-27
CN1358092A (zh) 2002-07-10
WO2001000205A1 (en) 2001-01-04
GB9914744D0 (en) 1999-08-25
PL352402A1 (en) 2003-08-25
ZA200109989B (en) 2003-02-26
AU5533200A (en) 2001-01-31
NO20016224L (no) 2002-02-12
BR0011880A (pt) 2002-03-19
CZ20014613A3 (cs) 2003-04-16
HUP0201878A2 (hu) 2003-08-28
MXPA01012936A (es) 2004-04-21
HUP0201878A3 (en) 2005-04-28
CA2375972A1 (en) 2001-01-04
RU2229289C2 (ru) 2004-05-27
SK18242001A3 (sk) 2003-02-04
IL147079A0 (en) 2002-08-14
NO20016224D0 (no) 2001-12-19
HK1049278A1 (zh) 2003-05-09
JP2003503349A (ja) 2003-01-28
TR200103699T2 (tr) 2002-04-22
EP1187606A1 (en) 2002-03-20

Similar Documents

Publication Publication Date Title
GB2254784B (en) Film-coated solid dosage form of anti-migraine drug
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
GEP20043324B (en) Purine Derivatives
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
LU91254I2 (fr) Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
BG103945A (bg) Производни на 4"-заместен-9-деоксо-9а-аза-9а- хомоеритромицин а
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
EP0740650A4 (en) CO-MEDICINAL PRODUCTS USED AS A REGULATED MEDICINE DELIVERY PROCESS
WO2005056524A3 (en) Therapeutic agents useful for treating pain
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
AU3850600A (en) Dalda analogs and their use
GB9305295D0 (en) Therapeutic compounds
BG104436A (bg) Използване на макролиди за лечение на рак и макуларна дегенерация
BG106180A (bg) Фармацевтичен състав, съдържащ сибутрамин и орлистат
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
MX9605458A (es) Derivados de amida y su uso terapeutico.
BG106209A (bg) Лекарствени средства
WO2005055933A3 (en) Treatment of psoriasis with rosiglitazone
TW200510370A (en) Urea derivatives
MY133438A (en) Morpholinobenzamide salts
AP9801235A0 (en) Erythromycin derivatives.
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
MY126998A (en) Substituted pyrroles.